IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:TSXV:IPA
DateTimeSourceHeadlineSymbolCompany
05/09/20228:18AMInvestorsHub NewsWireIPA's Subsidiary BioStrand Secures Second VLAIO Research Grant TSXV:IPAImmunoPrecise Antibodies Ltd
04/14/20227:06AMInvestorsHub NewsWireIPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings TSXV:IPAImmunoPrecise Antibodies Ltd
03/29/202210:48AMInvestorsHub NewsWireIPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence TSXV:IPAImmunoPrecise Antibodies Ltd
03/14/20228:04AMInvestorsHub NewsWireIPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense TSXV:IPAImmunoPrecise Antibodies Ltd
03/09/20227:07AMInvestorsHub NewsWireIPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03 TSXV:IPAImmunoPrecise Antibodies Ltd
04/08/20217:08AMInvestorsHub NewsWireImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease TSXV:IPAImmunoPrecise Antibodies Ltd
02/13/202112:25AMPR Newswire (Canada)TSX Venture Exchange Stock Maintenance Bulletins TSXV:IPAImmunoPrecise Antibodies Ltd
12/23/20206:30AMPR Newswire (Canada)ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange TSXV:IPAImmunoPrecise Antibodies Ltd
12/21/20207:12AMPR Newswire (Canada)ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year TSXV:IPAImmunoPrecise Antibodies Ltd
12/14/20206:20AMPR Newswire (Canada)ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate TSXV:IPAImmunoPrecise Antibodies Ltd
12/11/20206:45AMPR Newswire (Canada)ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2 TSXV:IPAImmunoPrecise Antibodies Ltd
11/25/202012:46PMPR Newswire (Canada)ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ TSXV:IPAImmunoPrecise Antibodies Ltd
11/23/20206:00AMPR Newswire (Canada)IPA Selects Polytope™ Formulations for Pre-Clinical Studies TSXV:IPAImmunoPrecise Antibodies Ltd
11/19/20206:00AMPR Newswire (Canada)ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease TSXV:IPAImmunoPrecise Antibodies Ltd
11/17/20207:01PMPR Newswire (Canada)ImmunoPrecise Antibodies Confirms Effective Date of Share Consolidation TSXV:IPAImmunoPrecise Antibodies Ltd
11/09/20208:11AMPR Newswire (Canada)ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration Statement TSXV:IPAImmunoPrecise Antibodies Ltd
11/04/20206:08PMPR Newswire (Canada)ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq Listing TSXV:IPAImmunoPrecise Antibodies Ltd
11/03/20206:30AMPR Newswire (Canada)ImmunoPrecise Antibodies and Mila Announce Strategic AI Partnership TSXV:IPAImmunoPrecise Antibodies Ltd
10/27/20206:28AMPR Newswire (Canada)ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic Products TSXV:IPAImmunoPrecise Antibodies Ltd
10/08/20206:30AMPR Newswire (Canada)IPA Delivers Lead Candidate Antibodies from B Cell Select™ Platform for at Home SARS-CoV-2 Diagnostic Test TSXV:IPAImmunoPrecise Antibodies Ltd
10/06/20206:30AMPR Newswire (Canada)IPA's CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN Television TSXV:IPAImmunoPrecise Antibodies Ltd
10/05/20206:30AMPR Newswire (Canada)ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & Friends TSXV:IPAImmunoPrecise Antibodies Ltd
09/29/20208:10AMPR Newswire (Canada)ImmunoPrecise Reports Revenue of $3.8 Million and Adjusted EBITDA of $932,000 for the First Quarter of Fiscal 2021 TSXV:IPAImmunoPrecise Antibodies Ltd
09/28/202010:59AMPR Newswire (Canada)IPA CEO Dr. Jennifer Bath to Appear Live Today on Bloomberg Television TSXV:IPAImmunoPrecise Antibodies Ltd
09/28/20206:30AMPR Newswire (Canada)ImmunoPrecise to Present at the Virtual Gravitas Healthcare Investor Day TSXV:IPAImmunoPrecise Antibodies Ltd
09/25/20206:30AMPR Newswire (Canada)ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical Trials TSXV:IPAImmunoPrecise Antibodies Ltd
09/22/20206:30AMPR Newswire (Canada)IPA Europe Significantly Expands its Capabilities, Releasing its Second-Generation B Cell Select ™ TSXV:IPAImmunoPrecise Antibodies Ltd
09/17/20206:30AMPR Newswire (Canada)ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks TSXV:IPAImmunoPrecise Antibodies Ltd
09/10/20206:30AMPR Newswire (Canada)ImmunoPrecise Commences Application Process to Dual List on NASDAQ TSXV:IPAImmunoPrecise Antibodies Ltd
09/09/20204:37PMPR Newswire (Canada)ImmunoPrecise Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 202... TSXV:IPAImmunoPrecise Antibodies Ltd
 Showing the most relevant articles for your search:TSXV:IPA
Your Recent History
TSX
BCE
BCE Inc
TSX
IVN
Ivanhoe Mi..
FX
CADUSD
Canadian D..
USOTC
XUII
Xumanii In..
FX
EURCAD
Euro vs Ca..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

Log in to ADVFN
Register Now
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:ca D:20230131 20:23:07